DNA topoisomerases as targets for antiprotozoal therapy

Mini Rev Med Chem. 2003 Sep;3(6):597-608. doi: 10.2174/1389557033487863.

Abstract

Diseases caused by parasitic protozoa present a health problem of immense magnitude, and there is an urgent need for safe and effective new therapies. DNA topoisomerases are clinically relevant targets for anti-cancer and anti-bacterial agents. Inhibitor studies on parasite topoisomerases have revealed that these enzymes have great promise as molecular targets for anti-parasitics, and have helped to dissect the basic biology of DNA topoisomerases in these organisms. This review provides a brief introduction to DNA topoisomerases and anti-topoisomerase drugs, and an overview of studies on protozoal DNA topoisomerases and their inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Anti-Infective Agents / chemistry
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use
  • Antiprotozoal Agents / chemistry
  • Antiprotozoal Agents / pharmacology
  • Antiprotozoal Agents / therapeutic use*
  • DNA Topoisomerases / metabolism
  • DNA, Protozoan / drug effects
  • DNA, Protozoan / metabolism
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Eukaryota / drug effects*
  • Eukaryota / enzymology
  • Humans
  • Protozoan Infections / drug therapy*
  • Protozoan Infections / parasitology
  • Topoisomerase Inhibitors*

Substances

  • Anti-Infective Agents
  • Antiprotozoal Agents
  • DNA, Protozoan
  • Enzyme Inhibitors
  • Topoisomerase Inhibitors
  • DNA Topoisomerases